Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969801 | 1.00 | GAA (0.60) | GAATDP1ALDH1A1TSHRNFKB1 | |
| SCHEMBL13202133 | 1.00 | GAA (0.60) | GAATDP1ALDH1A1TSHRNFKB1 | |
| SCHEMBL9029618 | 0.89 | ALOX5 (0.59) | GAATAS1R3TAS1R1TAS1R2TRPV1 | |
| SCHEMBL9029611 | 0.89 | ALOX5 (0.59) | GAATAS1R3TAS1R1TAS1R2TRPV1 | |
| SCHEMBL2969065 | 0.89 | SIGMAR1 (0.55) | GAATDP1ALDH1A1TSHRNFKB1 | |
| SCHEMBL2978208 | 0.89 | TRPV1 (0.58) | GAATDP1ALDH1A1TSHRNFKB1 | |
| SCHEMBL2969069 | 0.89 | SIGMAR1 (0.55) | GAATDP1ALDH1A1TSHRNFKB1 | |
| SCHEMBL2978204 | 0.89 | TRPV1 (0.58) | GAATDP1ALDH1A1TSHRNFKB1 | |
| SCHEMBL9808765 | 0.88 | EPHX2 (0.65) | GAATDP1ALDH1A1TSHRNFKB1 | |
| SCHEMBL2976977 | 0.88 | EPHX2 (0.65) | GAATDP1ALDH1A1TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767854-B2 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-0535250-B1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO (JP) | 1996-06-19 | — | — | EP | disclosed |
| EP-0705817-A1 | New cannamide derivatives and their use as allergy inhibitors | TSUMURA & CO. (JP) | 1996-04-10 | — | — | EP | disclosed |
| US-5344845-A | Methyl 4(4-acetoxy-3-methoxycinnamanide and salts as an immunosuppressive drug for allergic reactions | TSUMURA & CO. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0535250-A1 | NOVEL COMPOUNDS AND USE THEREOF AS MEDICINE | TSUMURA & CO. (JP) | 1993-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082463-A1 | N-substituted phenylacetamide derivative and pharmaceutical composition containing the same | HRH4, HRH2, CNR2 | GAA 4360/4885TDP1 4061/4885ALDH1A1 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.